Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

In Silico Trials for Cartilage Regenerative Medicine Applications

Project description

Finding a treatment for osteoarthritis virtually

One in eight adults worldwide suffers from osteoarthritis, which is a chronic disease that stiffens the joints. It is on the rise as populations age and obesity rates climb. Unfortunately, there is currently no treatment available to reverse the damage because the biology involves a messy collision of mechanical stress and inflammation. The ERC-funded INSTant CARMA project aims to build a detailed multiscale model of the knee, validated through laboratory and animal studies, to simulate disease progression and test treatments in virtual patient cohorts. From drug combinations to tissue-engineered implants, these in silico trials promise faster, safer development of therapies and could transform how osteoarthritis and other complex diseases, are treated.

Objective

Osteoarthritis (OA) is a highly prevalent disease, affecting 1 in 8 adults worldwide and is projected to increase by 60% in the next two decades. Due to the intricate interplay between multiple influencing factors such as mechanical loading and inflammation playing out over multiple length scales and tissue compartments, currently no disease-modifying drugs are available on the market. The INSTAnt CARMA project aims to harness the power of in silico trials to study OA onset and progression, as well as design endogenous (drugs) and exogenous (tissue engineered) therapies.
A multiscale multifactorial in silico model of the knee joint will be established and validated with dedicated in vitro and in vivo experiments. A continuous effort following targeted and untargeted approaches will take place to explore biological hypotheses and implement relevant model extensions. In parallel, computational upscaling tools will be implemented to prepare the model for execution of in silico trial simulations on virtual patient cohorts. The first in silico trial will investigate the effect of model-predicted drug combinations after experimental confirmation in a rodent model. The second trial will seek to optimize tissue engineered constructs for deep osteochondral defect regeneration, followed by experimental validation in a small and large animal model.
To realize its goals, INSTAnt CARMA can build on the well-received and published work on a wide range of in silico, in vitro and in vivo tools developed by the applicant and her team. Additionally, the work will benefit from the applicant’s extensive network and involvement in regulatory science for in silico medicine. This project will further accelerate the uptake of in silico testing strategies in the development of medical therapies in general and osteoarthritis in particular.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-COG

See all projects funded under this call

Host institution

UNIVERSITE DE LIEGE
Net EU contribution
€ 938 885,00
Address
PLACE DU 20 AOUT 7
4000 LIEGE
Belgium
Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 938 885,00

Beneficiaries (2)